Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-02-14 4:00 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | TANG CAPITAL PARTNERS LP | 3,220,000 7.5% | -400,000 (-11.05%) | View |
2024-02-12 09:00 am Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Sofinnova Partners SAS | 2,178,150 5.1% | 2,178,150 (New Position) | View |
2024-02-07 10:50 am Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | BML Investment Partners L.P. | 0 0% | -1,841,301 (Position Closed) | View |
2023-12-14 5:51 pm Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Genextra S.p.A. | 2,525,950 5.89% | 2,525,950 (New Position) | View |
2023-07-17 11:07 am Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | BML Investment Partners L.P. | 1,841,301 5.07% | 1,841,301 (New Position) | View |
2023-03-31 4:00 pm Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | TANG CAPITAL PARTNERS LP | 3,620,000 9.98% | 3,620,000 (New Position) | View |
2023-02-13 5:28 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | EPQ LLC CTYM PS | 1,576,720 4.4% | -1,286,376 (-44.93%) | View |
2022-07-08 12:56 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital World Investors | 0 0% | -2,501,882 (Position Closed) | View |
2022-02-11 6:06 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | PFIZER INC PFE | 600,000 2.01% | -1,456,377 (-70.82%) | View |
2022-02-11 2:48 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital World Investors | 2,501,882 8.4% | -668,849 (-21.09%) | View |
2022-02-11 12:22 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital Research Global Investors | 0 0% | -2,605,753 (Position Closed) | View |
2021-12-10 4:09 pm Unchanged | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 1,462,465 4.9% | 0 (Unchanged) | View |
2021-12-10 2:34 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 1,462,465 4.9% | -1,514,024 (-50.87%) | View |
2021-10-08 12:10 pm Unchanged | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 2,976,489 10% | 0 (Unchanged) | View |
2021-10-08 12:03 pm Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 2,976,489 10% | 396,034 (+15.35%) | View |
2021-04-27 11:35 am Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Lamond David | 2,048,938 6.9% | 93,773 (+4.80%) | View |
2021-03-25 4:17 pm Sale | 13G | QUINCE THERAPEUTICS, INC QNCX | PFIZER INC PFE | 2,056,377 7% | -86,995 (-4.06%) | View |
2021-03-10 2:10 pm Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital World Investors | 3,170,731 10.7% | 560,494 (+21.47%) | View |
2021-02-16 2:24 pm Unchanged | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 2,580,455 8.7% | 0 (Unchanged) | View |
2021-02-16 1:57 pm Purchase | 13G | QUINCE THERAPEUTICS, INC QNCX | Capital International Investors | 2,580,455 8.7% | 2,580,455 (New Position) | View |